Sardar Biglari Sells 2,749 Shares of VanEck Biotech ETF (NASDAQ:BBH) Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 2,749 shares of the firm’s stock in a transaction on Thursday, July 16th. The stock was sold at an average price of $16.70, for a total transaction of $45,908.30. Following the completion of the transaction, the insider directly owned 3,549,961 shares of the company’s stock, valued at approximately $59,284,348.70. This represents a 0.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Stock Down 1.0%

Shares of BBH opened at $204.23 on Friday. The stock has a 50-day moving average of $193.07 and a two-hundred day moving average of $191.95. VanEck Biotech ETF has a one year low of $154.75 and a one year high of $212.54.

Institutional Investors Weigh In On VanEck Biotech ETF

Large investors have recently bought and sold shares of the company. Empowered Funds LLC acquired a new position in VanEck Biotech ETF in the 4th quarter worth approximately $38,000. Flagship Harbor Advisors LLC acquired a new stake in VanEck Biotech ETF during the 4th quarter valued at approximately $47,000. Allworth Financial LP boosted its holdings in shares of VanEck Biotech ETF by 255.0% in the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after acquiring an additional 306 shares during the last quarter. Fifth Third Bancorp purchased a new stake in shares of VanEck Biotech ETF in the 1st quarter valued at $127,000. Finally, Huntington National Bank acquired a new stake in shares of VanEck Biotech ETF in the fourth quarter worth $132,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.